Cytochrome P450 enzymes and P-glycoprotein (CYP and P-gp)

Cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp) are integral components of the body's pharmacokinetic machinery that influence the disposition of doxycycline (Source: FDA Vibramycin Label). Although doxycycline undergoes minimal hepatic metabolism, its elimination rate is significantly increased by potent CYP inducers like carbamazepine and phenytoin, which can reduce its half-life by up to 50% (Source: StatPearls, Doxycycline). P-glycoprotein, an efflux transporter encoded by the ABCB1 gene, further regulates doxycycline levels by pumping the drug out of enterocytes and into the intestinal lumen, thereby limiting its bioavailability (Source: PMID 18454108). This coordinated activity between enzymes and transporters ensures the protection of tissues from xenobiotics but can also lead to sub-therapeutic antibiotic concentrations. In clinical practice, monitoring for drug-drug interactions involving these proteins is vital to prevent treatment failure in infections such as Lyme disease or respiratory tract infections (Source: Mayo Clinic Proceedings). Understanding these pathways is essential for optimizing dosing regimens and ensuring patient safety during multi-drug therapy.

Other names

CYP450ABCB1MDR1Multidrug resistance protein 1ATP-binding cassette sub-family B member 1Microsomal enzymes

Doxycycline is a substrate for P-glycoprotein-mediated efflux, and its systemic clearance is enhanced by the induction of Cytochrome P450 microsomal enzymes.